Free radical theory of autoimmunity

Theoretical Biology and Medical Modelling

Volumn 3, Issue , 2006, Pages

  Kannan, Subburaj ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; ANTINEOPLASTIC AGENT; ANTIOXIDANT; ASCORBIC ACID; CYTOKINE; FLAVANOID; FREE RADICAL; GLUTAREDOXIN; OXIDOREDUCTASE; POLYPHENOL DERIVATIVE; QUERCETIN; SELENIUM; SUPEROXIDE DISMUTASE; THIOREDOXIN REDUCTASE; TOLL LIKE RECEPTOR;

ANTIOXIDANT ACTIVITY; APOPTOSIS; AUTOIMMUNITY; CANCER CHEMOTHERAPY; CLINICAL PRACTICE; COLON CANCER; CONTROLLED STUDY; DISEASE SEVERITY; DNA DAMAGE; DRUG EFFECT; DRUG MECHANISM; EPIGENETICS; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IN VIVO STUDY; INCIDENCE; LUNG CANCER; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MOLECULAR MIMICRY; MULTIDRUG RESISTANCE; MULTIFACTORIAL INHERITANCE; ONCOLOGY; ONSET AGE; OXIDATIVE STRESS; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TREATMENT FAILURE; VIRUS INFECTION; ANIMAL; METABOLISM; PHYSIOLOGY;

ANIMALS; APOPTOSIS; AUTOIMMUNITY; DRUG RESISTANCE, MULTIPLE; FREE RADICALS; HUMANS; MOLECULAR MIMICRY; OXIDATIVE STRESS;

EID: 33746018989     PISSN: 17424682     EISSN: 17424682     Source Type: Journal    
DOI: 10.1186/1742-4682-3-22     Document Type: Review

References (151)

1. Gottesman MM, Fojo T, Bates SE: Multidrug resistance in cancer: role of ATP dependent transporters. Nat Rev Cancer 2002, 2:48-58.
2. Sood AK, Buller RE: Drug resistance in ovarian cancer: from the laboratory to the clinic. Obstet Gynecol 1998, 92:312-319.
3. Colvin OM, Friedman HS, Gamcsik MP, Fenselau C, Hilton J: Role of glutathione in cellular resistance to alkylating agents. Adv Enzyme Regul 1993, 33:19-26.
4. Green DR, Reed JC: Mitochondria and apoptosis. Science 1998, 281:1309-1312.
5. Begleiter A, Mowat M, Israels LG, Johnston JB: Chlorambucil in chronic lymphocytic leukemia: mechanism of action. Leuk Lymphoma 1996, 3-4:187-201.
6. Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC, Young LS: The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 1995, 11:1217-1228.
7. Thornberry NA, Lazebnik Y: Caspases: enemies within. Science 1998, 281:1312-1316.
8. Coultas L, Strasser A: The molecular control of DNA damageinduced cell death. Apoptosis 2000, 5:491-507.
9. Khanna KK, Jackson SP: DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 2001, 27:247-254.
10. Vistica DT: Cytotoxicity as an indicator for transport mechanism: Evidence that melphalan is transported by two leucine-preferring carrier systems in the L1210 murine leukemia cell. Biochim Biophys Acta 1979, 550:309-317.
11. Sanderson BJ, Shield AJ: Mutagenic damage to mammalian cells by therapeutic alkylating agents. Mutat Res 1996, 355:41-57.
12. Panasci L, Paiement JP, Christodoulopoulos G, Belenkov A, Malapetsa A, Aloyz R: Chlorambucil drug resistance in chronic lymphocytic leukemia: the emerging role of DNA repair. Clin Cancer Res 2001, 7:454-461.
13. Panasci L, Xu ZY, Bello V, Aloyz R: The role of DNA repair in nitrogen mustard drug resistance. Anti-Cancer Drugs 2002, 13:1-11.
14. Horton JK, Roy G, Piper JT, Van Houten B, Awasthi YC, Mitra S, Alaoui-Jamali MA, Boldogh I, Singhal SS: Characterization of a chlorambucil-resistant human ovarian carcinoma cell line overexpressing glutathione S-transferase mu. Biochem Pharmacol 1999, 58:693-702.
15. Roy G, Horton JK, Roy R, Denning T, Mitra S, Boldogh I: Acquired alkylating drug resistance of a human ovarian carcinoma cell line is unaffected by altered levels of pro- and anti-apoptotic proteins. Oncogene 2000, 19:141-150.
16. Boldogh I, Roy G, Lee MS, Bacsi A, Hazra TK, Bhakat KK, Das GC, Mitra S: Reduced DNA double strand breaks in chlorambucil resistant cells are related to high DNA-PKcs activity and low oxidative stress. Toxicology 2003, 193:137-52.
17. Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U: Classification of malignant lymphoid disorders. In Williams Hematology Volume Chapter 96. Sixth edition. Edited by: Lichtman MA, Beutler E, Kaushansky K, Kipps TJ,. Seligsohn U,. Prchal J. New York: McGraw-Hill; 2001:1137-1140.
18. Kwaan HC, Bongu A: The hyperviscosity syndromes. Semin Thromb Hemost 1999, 25:199-208.
19. Hirshberg B, Kramer MR, Lotem M, Barak V, Shustin L, Amir G, Ben-Yehuda D, Ben-Yehuda A: Chronic eosinophilic pneumonia associated with cutaneous T-cell lymphoma. Am J Hematol 1999, 60:143-7.
20. Roodman GD: Mechanisms of bone lesions in multiple myeloma and lymphoma. Cancer 1999, 80:1557-63.
21. Chubachi A, Miura I, Hatano Y, Ohshima A, Nishinari T, Miura AB: Syndrome of inappropriate secretion of antidiuretic hormone in patients with lymphoma-associated hemophagocytic syndrome. Ann Hematol 1995, 70:53-5.
22. Seymour JF, Gagel RF: Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. Blood 1993, 82:1383-94.
23. Lorigan PC, Woodings PL, Morgenstern GR, Scarffe JH: Tumour lysis syndrome, case report and review of the literature. Ann Oncol 1996, 7:631-6.
24. Pitkanen J, Peterson P: Autoimmune regulator: from loss of function to autoimmunity. Genes Immun 2003, 4:12-21.
25. Kuchroo VK, Umetsu DT, DeKruyff RH, Freeman GJ: The TIM gene family: emerging roles in immunity and disease. Nat Rev Immunol 2003, 6:454-62.
26. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, Rainbow DB, Hunter KM, Smith AN, Di Genova G, Herr MH, Dahlman I, Payne F, Smyth D, Lowe C, Twells RC, Howlett S, Healy B, Nutland S, Rance HE, Everett V, Smink LJ, Lam AC, Cordell HJ, Walker NM, Bordin C, Hulme J, Motzo C, Cucca F, Hess JF, Metzker ML, Rogers J, Gregory S, Allahabadia A, Nithiyananthan R, Tuomilehto-Wolf E, Tuomilehto J, Bingley P, Gillespie KM, Undlien DE, Ronningen KS, Guja C, Ionescu-Tirgoviste C, Savage DA, Maxwell AP, Carson DJ, Patterson CC, Franklyn JA, Clayton DG, Peterson LB, Wicker LS, Todd JA, Gough SC: Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003, 423:506-11.
27. Anderson MS, Venanzi ES, Klein L, Chen Z, Berzins SP, Turley SJ, von Boehmer H, Bronson R, Dierich A, Benoist C, Mathis D: Projection of an immunological self shadow within the thymus by the aire protein. Science 2002, 298:1395-401.
28. Mosmann TR, Coffman RL: TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989, 7:145-73.
29. Heath WR, Carbone FR: Cross-presentation in viral immunity and self-tolerance. Nat Rev Immunol 2001, 1:126-134.
30. Sakaguchi S: Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004, 22:531-62.
31. Akira S: Roles of STAT3 defined by tissue-specific gene targeting. Oncogene 2000, 19:2607-11.
32. Lenardo MJ: Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature 1991, 353:858-61.
33. Bleesing JJ, Straus SE, Fleisher TA: Autoimmune lymphoproliferative syndrome. A human disorder of abnormal lymphocyte survival. Pediatr Clin North Am 2000, 47:1291-310.
34. Refaeli Y, Van Parijs L, Abbas AK: Genetic models of abnormal apoptosis in lymphocytes. Immunol Rev 1999, 169:273-82.
35. Oosterwegel MA, Greenwald RJ, Mandelbrot DA, Lorsbach RB: Sharpe AH. CTLA-4 and T cell activation. Curr Opin Immunol 1999, 3:294-300.
36. Christen U, Benke D, Wolfe T, Rodrigo E, Rhode A, Hughes AC, Oldstone MB, von Herrath MG: Cure of prediabetic mice by viral infections involves lymphocyte recruitment along an IP-10 gradient. J Clin Invest 2004, 113:74-84.
37. Srinivasappa J, Saegusa J, Prabhakar BS, Gentry MK, Buchmeier MJ, Wiktor TJ, Koprowski H, Oldstone MB, Notkins AL: Molecular mimicry: frequency of reactivity of monoclonal antiviral antibodies with normal tissues. J Virol 1986, 57:397-401.
38. Hinson JA, Roberts DW: Role of covalent and noncovalent interactions in cell toxicity: effects on proteins. Annu Rev Pharmacol Toxicol 1986, 32:471-510.
39. Park BK, Kitteringham NR: Drug-protein conjugation and its immunological consequences. Drug Metabol Rev 1990, 22:87-144.
40. Katz-Levy Y, Neville KL, Girvin AM, Vanderlugt CL, Pope JG, Tan LJ, Miller SD: Endogenous presentation of self myelin epitopes by CNS-resident APCs in Theiler's virus-infected mice [see comments]. J Clin Invest 1999, 104:599-610.
41. Christen U, von Herrath MG: Induction, acceleration or prevention of autoimmunity by molecular mimicry. Molecular Immunology 2004, 40:1113-1120.
42. Gronski MA, Boulter JM, Moskophidis D, Nguyen LT, Holmberg K, Elford AR, Deenick EK, Kim HO, Penninger JM, Odermatt B, Gallimore A, Gascoigne NR, Ohashi PS: TCR affinity and negative regulation limit autoimmunity. Nat Med 2004, 11:1234-9.
43. Gleichmann E, Peters K, Lattmann E, Gleichmann H: Immunologic induction of reticulum cell sarcoma: donor-type lymphomas in the graft-versus-host model. Eur J Immunol 1976, 5:406-12.
44. 2. Eur J Immunol 1998, 28:1233-42.
45. Albers R, van der Pijl A, Bol M, Bleumink R, Seinen W, Pieters R: Distinct immunomodulation by autoimmunogenic xenobiotics in susceptible and resistant mice. Toxicol Appl Pharmacol 1999, 160:156-62.
46. Pieters R, Ezendam J, Nierkens S: Chemical-specific properties co-determine the type of adverse immune response. Autoimmun Rev 2003, 2:25-9.
47. Gut J: Molecular basis of halothane hepatitis. Arch Toxicol Suppl 1998, 20:3-17.
48. Gershwin ME, Ansari AA, Mackay IR, Nakanuma Y, Nishio A, Rowley MJ, Coppel RL: Primary biliary cirrhosis: an orchestrated immune response against epithelial cells. Immunol Rev 2000, 174:210-25.
49. Kretz-Rommel A, Rubin RL: Disruption of positive selection of thymocytes causes autoimmunity. Nat Med 2000, 6:298-305.
50. Zheng Y, Monestier M: Inhibitory signal override increases susceptibility to mercury-induced autoimmunity. J Immunol 2003, 171:1596-601.
51. Layland LE, Wulferink M, Dierkes S, Gleichmann E: Drug-induced autoantibody formation in mice: triggering by primed CD4+CD25- T cells, prevention by primed CD4+CD25+ T cells. Eur J Immunol 2004, 34:36-46.
52. Toubi E, Shoenfeld Y: Toll-like receptors and their role in the development of autoimmune diseases. Autoimmunity 2004, 37:183-8.
53. Anderson KV, Bokla L, Nusslein-Volhard C: Establishment of dorsal-ventral polarity in the Drosophilaembryo: the induction of polarity by the Toll gene product. Cell 1985, 42:791-798.
54. Abbas AK, Lichtman AH: Immunity to microbes. In Cellular and Molecular Immunology Volume Chapter 15. Firth edition. Edited by: Abbas AK, Lichtman AH. Philadelphia: Saunders; 2005:345-366.
55. Vinuesa CG, Goodnow CC: Immunology: DNA drives autoimmunity. Nature 2002, 416:595-8.
56. Hannum LG, Ni D, Haberman AM, Weigert MG, Shlomchik MJ: A disease-related rheumatoid factor autoantibody is not tolerized in a normal mouse: implications for the origins of autoantibodies in autoimmune disease. J Exp Med 1996, 184:1269-78.
57. Anders HJ, Vielhauer V, Eis V, Linde Y, Kretzler M, Perez de Lema G, Strutz F, Bauer S, Rutz M, Wagner H, Grone HJ, Schlondorff D: Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice. FASEB J 2004, 18:534-6.
58. Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R: Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2001, 2:947-50.
59. Eriksson U, Ricci R, Hunziker L, Kurrer MO, Oudit GY, Watts TH, Sonderegger I, Bachmaier K, Kopf M, Penninger JM: Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nat Med 2003, 9:1484-90. (Erratum in: Nat Med. 2004 Jan;10(1):105)
60. Shi Y, Evans JE, Rock KL: Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003, 425:516-21.
61. Matzinger P: Tolerance, danger, and the extended family. Annu Rev Immunol 1994, 12:991-1045.
62. Werling D, Jungi TW: TOLL-like receptors linking innate and adaptive immune response. Vet Immunol Immunopathol 2003, 91:1-12.
63. Lu Q, Lemke G: Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science 2001, 293:306-11.
64. Beutler B: Inferences, questions and possibilities in Toll-like receptor signalling. Nature 2004, 430:257-63.
65. Yamamoto M, Takeda K, Akira S: TIR domain-containing adaptors define the specificity of TLR signaling. Mol Immunol 2004, 40:861-8.
66. Kimoto M, Nagasawa K, Miyake K: Role of TLR4/MD-2 and RP105/MD-1 in innate recognition of lipopolysaccharide. Scand J Infect Dis 2003, 35:568-72.
67. Anders HJ, Banas B, Schlondorff D: Signaling danger: toll-like receptors and their potential roles in kidney disease. J Am Soc Nephrol 2004, 15:854-67.
68. Berkeredjian-Ding IB, Wagner M, Hornung V, Giese T, Schnurr M, Endres S, Hartmann G: Plasmacytoid Dendritic Cells Control TLR7 Sensitivity of Naive B Cells via Type I IFN. J Immunol 2005, 174:4043-50.
69. Lenert P, Brummel R, Field EH, Ashman RF: TLR-9 Activation of Marginal Zone B Cells in Lupus Mice Regulates Immunity Through Increased IL-10 Production. J Clin Immunol 2005, 25:29-40.
70. Hamilton-Williams EE, Lang A, Benke D, Davey GM, Wiesmuller KH, Kurts C: Cutting edge: TLR ligands are not sufficient to break cross-tolerance to self-antigens. J Immunol 2005, 174:1159-63.
71. Coleman CN, Blakely WF, Fike JR, MacVittie TJ, Metting NF, Mitchell JB, Moulder JE, Preston RJ, Seed TM, Stone HB, Tofilon PJ, Wong RS: Molecular and cellular biology of moderate-dose (1-10 Gy) radiation and potential mechanisms of radiation protection: report of a workshop at Bethesda, Maryland, December 17-18, 2001. Radiat Res 2003, 159:812-34.
72. Lin M, Rippe RA, Brittenham G, Tsukamoto H: Role of iron in NF-kappa B activation and cytokine gene expression by rat hepatic macrophages. Am J Physiol 1997, 272:G1355-G1364.
73. Matata BM, Galinanes M: Peroxynitrite is an essential component of cytokines production mechanism in human monocytes through modulation of nuclear factor-kappa B DNA binding activity. J Biol Chem 2002, 277:2330-2335.
74. Xiong S, She H, Takeuchi H, Han B, Engelhardt JF, Barton CH, Zandi E, Giulivi C, Tsukamoto H: Signaling role of intracellular iron in NF-kappaB activation. J Biol Chem 2003, 278:17646-17654.
75. Dent P, Yacoub A, Contessa AJ, Caron R, Amorino G, Valerie K, Hagan MP, Grant S, Schmidtullrixh R: Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiation Research 2003, 159:283-300.
76. Wang J, Kannan S, Li H, Khan MF: Cytokine gene expression and activation of NF-kappa B in aniline-induced splenic toxicity. Toxicol Appl Pharmacol 2005, 203:36-44.
77. Denham JW, Hauer-Jensen M: The radiotherapeutic injury - a complex 'wound'. Radiotherapy Oncology 2002, 63:129-145.
78. Riley PA: Free radicals in biology: oxidative stress and the effects of ionizing radiation. International Journal of Radiation Biology 1994, 65:27-33.
79. Wink DA, Mitchell JB: Chemical biology of nitric oxide: insights into regulatory, cytotoxic and cytoprotective mechanisms of nitric oxide. Free Radicals in Biology and Medicine 1998, 25:434-456.
80. Nathan C: Specificity of a third kind: reactive oxygen and nitrogen intermediates in cell signaling. Journal of Clinical Investigation 2003, 111:769-778.
81. Mikkelsen RB, Wardman P: Biological chemistry of reactive oxygen and nitrogen and radiation-induced signal transduction mechanisms. Oncogene 2003, 22:5734-54.
82. Lonergan PE, Martin DS, Horrobin DF, Lynch MA: Neuroprotective effect of eicosapentaenoic acid in hippocampus of rats exposed to gamma-irradiation. J Biol Chem 2002, 277:20804-20811.
83. Tsuji C, Shioya S, Hirota Y, Fukuyama N, Kurita D, Tanigaki T, Ohta Y, Nakazawa H: Increased production of nitrotyrosine in lung tissue of rats with radiation-induced acute lung injury. Am J Physiol Lung Cell Mol Physiol 2000, 278:719-25.
84. Giaid A, Lehnert SM, Chehayeb B, Chehayeb D, Kaplan I, Shenouda G: Inducible nitric oxide synthase and nitrotyrosine in mice with radiation-induced lung damage. Am J Clin Oncol 2003, 26:e67-72.
85. Jack CI, Cottier B, Jackson MJ, Cassapi L, Fraser WD, Hind CR: Indicators of free radical activity in patients developing radiation pneumonitis. Int J Radiat Oncol Biol Phys 1996, 34:149-54.
86. Vujaskovic Z, Anscher MS, Feng QF, Rabbani ZN, Amin K, Samulski TS, Dewhirst MW, Haroon ZA: Radiation-induced hypoxia may perpetuate late normal tissue injury. Int J Radiat Oncol Biol Phys 2001, 50:851-5.
87. Duranteau J, Chandel NS, Kulisz A, Shao Z, Schumacker PT: Intracellular signaling by reactive oxygen species during hypoxia in cardiomyocytes. J Biol Chem 1998, 273:11619-24.
88. Killilea DW, Hester R, Balczon R, Babal P, Gillespie MN: Free radical production in hypoxic pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2000, 279:L408-12.
89. Li C, Jackson RM: Reactive species mechanisms of cellular hypoxia-reoxygenation injury. Am J Physiol Cell Physiol 2002, 282:C227-41.
90. Clemens MR, Ladner C, Schmidt H, Ehninger G, Einsele H, Buhler E, Waller HD, Gey KF: Decreased essential antioxidants and increased lipid hydroperoxides following high-dose radiochemotherapy. Free Radical Research Communications 1989, 7:227-232.
91. Umegaki K, Sugisawa A, Shin SJ, Yamada K, Sano M: Different onsets of oxidative damage to DNA and lipids in bone marrow and liver in rats given total body irradiation. Free Radic Biol Med 2001, 31:1066-74.
92. Srivastava M, Chandra D, Kale RK: Modulation of radiation-induced changes in the xanthine oxidoreductase system in the livers of mice by its inhibitors. Radiat Res 2002, 157:290-7.
93. Korystov YN, Dobrovinskaya OR, Shaposhnikova VV, Eidus Kh L: Role of arachidonic acid metabolism in thymocyte apoptosis after irradiation. FEBS Lett 1996, 388:238-41.
94. Soto C: Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci 2003, 4:49-60.
95. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM: Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006, 5:219-34.
96. Hipfner DR, Deeley RG, Cole SP: Structural, mechanistic and clinical aspects of MRP1. Biochim Biophys Acta 1999, 1461:359-376.
97. Konig J, Rost D, Cui Y, Keppler D: Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology 1999, 29:1156-1163.
98. Baer R, Stephen L, Dodge K, O'Loughlin KL, Minderman H, Caligiuri MA, Anastasi J, Powell BL, Kolitz JE, Schiffer CA, Bloomfield CD, Larson RA: Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 2002, 100:1224-1232.
99. Dantzig AH, de Alwis DP, Burgess M: Considerations in the design and development of transport inhibitors as adjuncts to drug therapy. Adv Drug Deliv Rev 2003, 55:133-150.
100. Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H, Haga N: Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci 2003, 94:15-21.
101. Pelicano H, Carney D, Huang P: ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 2004, 7:97-110.
102. Schor NF, Kagan VE, Liang Y, Yan Ch, Tyurina Y, Tyurin V, Nylander KD: Exploiting oxidative stress and signaling in chemotherapy of resistant neoplasms. Biochemistry (Mosc) 2004, 69:38-44.
103. Pennington JD, Wang TJ, Nguyen P, Sun L, Bisht K, Smart D, Gius D: Redox-sensitive signaling factors as a novel molecular target for cancer therapy. Drug Resist Updat 2005, 8:322-30.
104. Mahajan S, Atkins WM: The chemistry and biology of inhibitors and pro-drugs targeted to glutathione S-transferases. Cell Mol Life Sci 2005, 62:221-33.
105. Mates JM, Perez-Gomez C, De Castro IN: Antioxidant enzymes and human diseases. Clin Biochem 1999, 32:595-603.
106. McCall MR, Frei B: Can antioxidant vitamins materially reduce oxidative damage in humans? Free Rad Biol Med 1999, 26:1034-1053.
107. Sies H, Stahl W, Sevanian A: Nutritional, dietary and postprandial oxidative stress. J Nutr 2005, 135:969-972.
108. Sun Y, Oberley LW: Redox regulation of transcriptional activators. Free Rad Biol Med 1996, 21:335-348.
109. Powis G, Mustacich D, Coon A: The role of the redox protein thioredoxin in cell growth and cancer. Free Radic Biol Med 2000, 29:312-22.
110. Smart DK, Ortiz KL, Mattson D, Bradbury CM, Bisht KS, Sieck LK, Brechbiel MW, Gius D: Thioredoxin reductase as a potential molecular target for anticancer agents that induce oxidative stress. Cancer Res 2004, 64:6716-6724.
111. Sun QA, Wu Y, Zappacosta F, Jeang KT, Lee BJ, Hatfield DL, Gladyshev VN: Redox regulation of cell signaling by selenocysteine in mammalian thioredoxin reductases. J Biol Chem 1999, 274:24522-24530.
112. Andersson M, Gunne H, Agerberth B, Boman A, Bergman T, Olsson B, Dagerlind A, Wigzell H, Boman HG, Gudmundsson GH: NK-lysin, structure and function of a novel effector molecule of porcine T and NK cells. Vet Immunol Immunopathol 1996, 54:123-6.
113. Wipf P, Hopkins TD, Jung JK, Rodriguez S, Birmingham A, Southwick EC, Lazo JS, Powis G: New inhibitors of the thioredoxin-thioredoxin reductase system based on a naphthoquinone spiroketal natural product lead. Bioorg Med Chem Lett 2001, 11:2637-41.
114. Engman L, Al-Maharik N, McNaughton M, Birmingham A, Powis G: Thioredoxin reductase and cancer cell growth inhibition by organotellurium antioxidants. Anticancer Drugs 2003, 14:153-61.
115. Becker K, Gromer S, Schirmer RH, Muller S: Thioredoxin reductase as a pathophysiological factor and drug target. Eur J Biochem 2000, 267:6118-25.
116. Iwao-Koizumi K, Matoba R, Ueno N, Kim SJ, Ando A, Miyoshi Y, Maeda E, Noguchi S, Kato K: Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 2005, 23:422-31.
117. Martins EA, Mori L, Birnboim HC, Meneghini R: Menadione-resistant Chinese hamster cell variants are cross-resistant to hydrogen peroxide and exhibit stable chromosomal and biochemical alterations. Mol Cell Biochem 1992, 118:181-9.
118. Hayes JD, Pulford DJ: The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995, 30:445-600.
119. Liu RM, Hu H, Robison TW, Forman HJ: Increased gammaglutamylcysteine synthetase and gamma-glutamyl transpeptidase activities enhance resistance of rat lung epithelial L2 cells to quinine toxicity. Am J Respir Cell Mol Biol 1996, 14:192-197.
120. Schiff R, Reddy P, Ahotupa M, Coronado-Heinsohn E, Grim M, Hilsenbeck SG, Lawrence R, Deneke S, Herrera R, Chamness GC, Fuqua SA, Brown PH, Osborne CK: Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst 2000, 92:1926-34.
121. Kalinina EV, Saprin AN, Solomka VS, Shcherbak NP, Chermnykh NS, Piruzian LA: [Role of the antioxidant system and redox-dependent regulation of transcription factors bcl-2 and p53 in forming resistance of human K562 erythroleukemia cells to doxorubicin]. Vopr Onkol 2001, 47:595-600.
122. Cullen KJ, Newkirk KA, Schumaker LM, Aldosari N, Rone JD, Haddad BR: Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors. Cancer Res 2003, 63:8097-102.
123. Kamada K, Goto S, Okunaga T, Ihara Y, Tsuji K, Kawai Y, Uchida K, Osawa T, Matsuo T, Nagata I, Kondo T: Nuclear glutathione Stransferase pi prevents apoptosis by reducing the oxidative stress-induced formation of exocyclic DNA products. Free Radic Biol Med 2004, 37:1875-84.
124. Lillig CH, Lonn ME, Enoksson M, Fernandes AP, Holmgren A: Short interfering RNA-mediated silencing of glutaredoxin 2 increases the sensitivity of HeLa cells toward doxorubicin and phenylarsine oxide. Proc Natl Acad Sci U S A 2004, 101:13227-32.
125. Depeille P, Cuq P, Mary S, Passagne I, Evrard A, Cupissol D, Vian L: Glutathione S-transferase M1 and multidrug resistance protein 1 act in synergy to protect melanoma cells from vincristine effects. Mol Pharmacol 2004, 65:897-905.
126. Beer SM, Taylor ER, Brown SE, Dahm CC, Costa NJ, Runswick MJ, Murphy MP: Glutaredoxin 2 catalyzes the reversible oxidation and glutathionylation of mitochondrial membrane thiol proteins: implications for mitochondrial redox regulation and antioxidant defense. J Biol Chem 2004, 279:47939-51.
127. Tarumoto T, Nagai T, Ohmine K, Miyoshi T, Nakamura M, Kondo T, Mitsugi K, Nakano S, Muroi K, Komatsu N, Ozawa K: Ascorbic acid restores sensitivity to imatinib via suppression of Nrf2-dependent gene expression in the imatinib-resistant cell line. Exp Hematol 2004, 32:375-81.
128. Lee HC, Kim DW, Jung KY, Park IC, Park MJ, Kim MS, Woo SH, Rhee CH, Yoo H, Lee SH, Hong SI: Increased expression of antioxidant enzymes in radioresistant variant from U251 human glioblastoma cell line. Int J Mol Med 2004, 13:883-7.
129. Duvoix A, Schnekenburger M, Delhalle S, Blasius R, Borde-Chiche P, Morceau F, Dicato M, Diederich M: Expression of glutathione Stransferase P1-1 in leukemic cells is regulated by inducible AP-1 binding. Cancer Lett 2004, 216:207-19.
130. Enoksson M, Fernandes AP, Prast S, Lillig CH, Holmgren A, Orrenius S: Overexpression of glutaredoxin 2 attenuates apoptosis by preventing cytochrome c release. Biochem Biophys Res Commun 2005, 327:774-9.
131. Samudio I, Konopleva M, Hail N Jr, Shi YX, McQueen T, Hsu T, Evans R, Honda T, Gribble GW, Sporn M, Gilbert HF, Safe S, Andreeff M: 2-Cyano-3,12-dioxooleana-1,9-dien-28-imidazolide (CDDO-Im) directly targets mitochondrial glutathione to induce apoptosis in pancreatic cancer. J Biol Chem 2005, 280:36273-82.
132. Redell MS, Tweardy DJ: Targeting transcription factors for cancer therapy. Curr Pharm Des 2005, 11:2873-87.
133. Lazo JS, Kuo SM, Woo ES, Pitt BR: The protein thiol metallothionein as an antioxidant and protectant against antineoplastic drugs. Chem Biol Interact 1998, 111-112:255-62.
134. Jiang YE: Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002, 21:2245-2252.
135. Knekt P, Jarvinen R, Seppanen R, Rissanen A, Aromaa A, Heinonen OP, Albanes D, Heinonen M, Pukkala E, Teppo L: Dietary antioxidants and the risk of lung-cancer. Am J Epidemiol 1991, 134:471-479.
136. Damianaki A, Bakogeorgou E, Kampa M, Notas G, Hatzoglou A, Panagiotou S, Gemetzi C, Kouroumalis E, Martin PM, Castanas E: Potent inhibitory action of red wine polyphenols on human breast cancer cells. J Cell Biochem 2000, 78:429-441.
137. Clark LC, Combs GF, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Lesher JL, Park HK, Sanders BB, Smith CL, Taylor JR: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin a randomized controlled trial - a randomized controlled trial. J Am Med Assoc 1996, 276:1957-1963.
138. Voehringer DW: BCL-2 and glutathione: alterations in cellular redox state that regulate apoptosis sensitivity. Free Rad Biol Med 1999, 27:945-950.
139. McEligot AJ, Yang S, Meyskens FL: Redox regulation by intrinsic species and extrinsic nutrients in normal and cancer cells. Ann Rev Nutr 2005, 25:261-295.
140. Kern JC, Kehrer JP: Free radicals and apoptosis: relationships with glutathione, thioredoxin and the Bcl family of proteins. Front Biosci 2005, 10:1727-1738.
141. Evens AM: Motexafin gadolinium: a redox-active tumor selective agent for the treatment of cancer. Curr Opin Oncol 2004, 16:576-580.
142. Schulze-Osthoff K, Los M, Baeuerle PA: Redox signaling by transcription factors NF-kappa B and AP-1 in lymphocytes. Biochem Pharmacol 1995, 50:735-41.
143. Chakraborti S, Chakraborti T: Oxidant-mediated activation of mitogen-activated protein kinases and nuclear transcription factors in the cardiovascular system: a brief overview. Cell Signal 1998, 10:675-83.
144. Kannan S: Molecular mechanism of chemotherapeutic drug(s)-, induced autoimmunity: a mitochondrial-lysosomal axis theory. Med Hypotheses 2005, 64:1068.
145. Kannan S: Molecular basis of the drug resistance induced autoimmunity: a redox theory. Med Hypotheses 2005, 64:882-3.
146. Galinanes M, Matata BM: Protein nitration is predominantly mediated by a peroxynitrite-dependent pathway in cultured human leucocytes. Biochem J 2002, 367:467-73.
147. Marnett LJ: Oxy radicals, lipid peroxidation and DNA damage. Toxicology 2002, 181-182:219-22.
148. Gaston BM, Carver J, Doctor A, Palmer LA: S-nitrosylation signaling in cell biology. Mol Interv 2003, 3:253-63.
149. Dent P, Yacoub A, Fisher PB, Hagan MP, Grant S: MAPK pathways in radiation responses. Oncogene 2003, 22:5885-96.
150. Rahman I, Marwick J, Kirkham P: Redox modulation of chromatin remodeling: impact on histone acetylation and deacetylation, NF-kappaB and pro-inflammatory gene expression. Biochem Pharmacol 2004, 68:1255-67.
151. Giordano FJ: Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 2005, 115:500-508.